MedTrace Logo

Patient-Reported Outcomes in Allogeneic Stem Cell Transplantation and CAR-T Therapy

NCT07289087 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 162

Last updated 2025-12-17

No results posted yet for this study

Summary

3.1. Overview Prospective, multicenter, observational cohort study comparing short-term PROs measured with the HM-PRO between two exposure groups: patients undergoing allogeneic stem cell transplantation (allo-SCT) and patients receiving CAR-T cell therapy. Patients will be enrolled at hospital admission for the index inpatient procedure and followed through the inpatient stay (admission → discharge). The study is non-randomized and designed to describe trajectories of symptoms and HRQoL and to estimate the between-group difference in deterioration of HM-PRO scores (primary estimand: mean difference in change score, CAR-T vs allo-SCT).

Conditions

  • Quality of Life
  • Patient Reported Outcome (PRO)
  • Allogeneic Blood and Marrow Transplantation (BMT)
  • CAR T Cell Therapy

Sponsors & Collaborators

  • Associazione Qol-one

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-02-15
Primary Completion
2027-03-01
Completion
2027-04-01

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07289087 on ClinicalTrials.gov